Market capitalization | SEK1.80b |
Enterprise Value | SEK1.72b |
P/E (TTM) P/E ratio | 64.51 |
EV/Sales (TTM) EV/Sales | 13.27 |
P/S ratio (TTM) P/S ratio | 13.88 |
P/B ratio (TTM) P/B ratio | 8.10 |
Revenue growth (TTM) Revenue growth | -17.19% |
Revenue (TTM) Revenue | SEK129.73m |
EBIT (operating result TTM) EBIT | SEK27.57m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a Genovis forecast:
2 Analysts have issued a Genovis forecast:
Sep '24 |
+/-
%
|
||
Revenue | 130 130 |
17%
17%
|
|
Gross Profit | 28 28 |
50%
50%
|
|
EBITDA | 39 39 |
38%
38%
|
EBIT (Operating Income) EBIT | 28 28 |
50%
50%
|
Net Profit | 28 28 |
49%
49%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genovis AB engages in the research and development of enzyme products. Its product portfolio includes SmartEnzymes, which offers to pharmaceutical and medical device industries tools that facilitate the development of new treatment methods and diagnostics. The company was founded by Inga Sarah Maria Fredriksson in 1999 and is headquartered in Lund, Sweden.
Head office | Sweden |
CEO | Fredrik Olsson |
Employees | 37 |
Founded | 1999 |
Website | www.genovis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.